Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients
- 20 April 2018
- journal article
- research article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 43 (5) , 675-681
Abstract
What is known and objective For analysis of blood concentrations of everolimus, many hospital laboratories use either latex agglutination turbidimetric immunoassay (LTIA) or electrochemiluminescence immunoassay (ECLIA). However, no studies have compared both immunoassay methods under the same conditions. Accordingly, in this study, we compared everolimus blood concentrations obtained by LTIA and ECLIA in renal transplant patients. Methods Blood samples (n = 230) from 60 renal transplant patients (19 female and 41 male) were evaluated using both immunoassays. Subsequently, we switched the assay for detection of everolimus blood concentrations from LTIA to ECLIA as a clinical application. Three quality control (QC) samples for LTIA were analysed using ECLIA, and 3 QC samples for ECLIA were analysed using LTIA. Results The Deming regression of ECLIA versus LTIA generated the following parameters: slope, 1.0067 and intercept, 1.7489 ng/mL, in the analysis of 230 samples. Bland‐Altman analysis showed an average positive bias of 1.73 ng/mL between ECLIA and LTIA. When the clinical apparatus was switched from LTIA to ECLIA, the average everolimus blood concentration assayed by LTIA before switching was 3.57 ng/mL, whereas that by ECLIA after switching in the same patients taking the same daily dose (mean: 1.43 mg/day) was 5.85 ng/mL. The QCs assayed using LTIA were lower by an average of 67.3% (range: 55.8%‐79.5%) for ECLIA, and in the same 230 samples from patients, the everolimus blood concentrations assayed by LTIA were lower by an average of 67.4% (range: 37.1%‐114.5%) of ECLIA. What is new and conclusion Analysis of everolimus concentrations by immunoassays with high precision and accuracy is required to ensure long‐term survival of transplant recipients. Although the concentrations of QCs and calibrators of everolimus in LTIA were previously corrected to 70% concentration because of cross‐reactivity with everolimus metabolites, these adjustments may need to be reviewed.Keywords
This publication has 21 references indexed in Scilit:
- Everolimus with low‐dose tacrolimus in simultaneous pancreas and kidney transplantationClinical Transplantation, 2014
- Population Pharmacokinetics of Everolimus in Cardiac RecipientsTherapeutic Drug Monitoring, 2012
- CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant RecipientsTransplantation, 2011
- Optimal Everolimus Concentration Is Associated With Risk Reduction for Acute Rejection in De Novo Renal Transplant RecipientsTransplantation, 2010
- Crossreactivity of Isolated Everolimus Metabolites With the Innofluor Certican Immunoassay for Therapeutic Drug Monitoring of EverolimusTherapeutic Drug Monitoring, 2007
- MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantationJournal of Surgical Oncology, 2007
- Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety dataClinical Transplantation, 2005
- Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect ModelingAmerican Journal of Transplantation, 2004
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004
- Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RADBritish Journal of Clinical Pharmacology, 2000